Revvity (NYSE:RVTY) Rating Increased to Hold at Royal Bank Of Canada

Revvity (NYSE:RVTY) was upgraded by equities research analysts at Royal Bank Of Canada to a “hold” rating in a research note issued to investors on Tuesday, Zacks reports.

A number of other research firms have also issued reports on RVTY. TD Cowen restated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Sanford C. Bernstein started coverage on shares of Revvity in a research note on Friday, June 26th. They issued a “market perform” rating and a $115.00 price objective for the company. Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. JPMorgan Chase & Co. cut their target price on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, Robert W. Baird set a $117.00 target price on Revvity in a report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Revvity presently has a consensus rating of “Hold” and an average price target of $110.58.

Revvity Trading Down 1.6%

Shares of RVTY opened at $126.59 on Tuesday. The business’s 50-day moving average price is $115.22 and its 200 day moving average price is $101.55. The stock has a market capitalization of $14.13 billion, a P/E ratio of 60.28, a P/E/G ratio of 2.34 and a beta of 1.09. Revvity has a 1-year low of $81.22 and a 1-year high of $130.07. The company has a current ratio of 1.80, a quick ratio of 1.50 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million during the quarter, compared to analyst estimates of $702.96 million. During the same period in the prior year, the firm earned $1.18 earnings per share. The business’s quarterly revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts expect that Revvity will post 5.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its position in Revvity by 19.8% during the first quarter. California State Teachers Retirement System now owns 133,809 shares of the company’s stock valued at $11,723,000 after purchasing an additional 22,075 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in Revvity in the 2nd quarter worth about $78,766,000. Corient Private Wealth LLC raised its stake in shares of Revvity by 985.0% during the 4th quarter. Corient Private Wealth LLC now owns 126,568 shares of the company’s stock worth $12,245,000 after purchasing an additional 114,903 shares in the last quarter. Diamond Hill Capital Management Inc. raised its stake in shares of Revvity by 6.3% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 426,899 shares of the company’s stock worth $41,302,000 after purchasing an additional 25,233 shares in the last quarter. Finally, Tocqueville Asset Management L.P. acquired a new stake in shares of Revvity during the 2nd quarter valued at about $4,791,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.